Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolaj Frost

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Journal of Personalized Medicine|March 26, 2025
Non-Small Cell Lung Cancer Patients with Skip-N2 Metastases Have Similar Survival to N1 Patients-A Multicenter AnalysisGeorg Schlachtenberger, Simon Schallenberg, Fabian Doerr, et al.
Cancers|June 10, 2022
Reducing Immunosuppression in Patients with De Novo Lung Carcinoma after Liver Transplantation Could Significantly Prolong SurvivalSina Pesthy, Elisa Wegener, Ramin Raul Ossami Saidy, et al.
Translational Lung Cancer Research|March 15, 2021
KRAS<sup>G12C</sup>/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinomaNikolaj Frost, Jens Kollmeier, Claudia Vollbrecht, et al.
Patient Education and Counseling|March 20, 2026
Patient-oriented navigation in stroke and lung cancer patients: Results on feasibility and efficacy of two randomized controlled trials in GermanyKathrin Gödde, Alice Schneider, Raphael Kohl, et al.
Lung Cancer (Amsterdam, Netherlands)|July 8, 2022
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysisNikolaj Frost, Julia Roeper, Janna-Lisa Velthaus, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access programNikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2023
Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysisNikolaj Frost, Kristina Unger, Torsten Gerriet Blum, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 7, 2019
DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancerPhilipp Jurmeister, Anne Schöler, Alexander Arnold, et al.
Journal of Neuro-Oncology|February 15, 2024
Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resectionDavid Wasilewski, Julia Onken, Paul Höricke, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2022
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgeryTobias Boch, Nikolaj Frost, Linna Sommer, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Journal of Personalized Medicine|March 26, 2025
Non-Small Cell Lung Cancer Patients with Skip-N2 Metastases Have Similar Survival to N1 Patients-A Multicenter AnalysisGeorg Schlachtenberger, Simon Schallenberg, Fabian Doerr, et al.
Cancers|June 10, 2022
Reducing Immunosuppression in Patients with De Novo Lung Carcinoma after Liver Transplantation Could Significantly Prolong SurvivalSina Pesthy, Elisa Wegener, Ramin Raul Ossami Saidy, et al.
Translational Lung Cancer Research|March 15, 2021
KRAS<sup>G12C</sup>/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinomaNikolaj Frost, Jens Kollmeier, Claudia Vollbrecht, et al.
Patient Education and Counseling|March 20, 2026
Patient-oriented navigation in stroke and lung cancer patients: Results on feasibility and efficacy of two randomized controlled trials in GermanyKathrin Gödde, Alice Schneider, Raphael Kohl, et al.
Lung Cancer (Amsterdam, Netherlands)|July 8, 2022
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysisNikolaj Frost, Julia Roeper, Janna-Lisa Velthaus, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access programNikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2023
Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysisNikolaj Frost, Kristina Unger, Torsten Gerriet Blum, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 7, 2019
DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancerPhilipp Jurmeister, Anne Schöler, Alexander Arnold, et al.
Journal of Neuro-Oncology|February 15, 2024
Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resectionDavid Wasilewski, Julia Onken, Paul Höricke, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2022
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgeryTobias Boch, Nikolaj Frost, Linna Sommer, et al.
Pageof 7